Doliral food supplement for pelvic pain and quality of life in endometriosis
Official title: Experimental Study of Quality of Life in Patients With Endometriosis and Pelvic Pain Treated With Doliral Dietary Supplementation Versus Placebo.
Run by Arafarma Group, S.A. · NCT07393958 · Data updated 2026-11-12
This trial will test whether the food supplement Doliral can reduce pelvic pain and improve quality of life for reproductive-age women with diagnosed endometriosis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 60 (estimated) |
| Sponsor | Arafarma Group, S.A. Industry-sponsored |
| Locations | 1 site (Barcelona) |
| Status | Recruiting |
| Started | February 26, 2026 |
| Main results expected | August 1, 2027 |
| Study ends | September 15, 2027 |
| Registry record updated | October 30, 2026 |
| Trial ID | NCT07393958 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women of reproductive age with laparoscopically or imaging-confirmed endometriosis (ASRM stage I–III) who have had pelvic pain with VAS > 4 in the past three months and who do not currently need surgery are the intended participants.
✕Probably not a fit
Patients with more advanced disease (e.g., stage IV), recent related surgery, recent changes in hormone therapy, on excluded analgesic regimens, or who require surgical treatment are unlikely to benefit from this supplement in the context of this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants are randomized 1:1 (30 receive Doliral, 30 receive placebo) and stratified by whether they are on hormonal therapy. Treatment is given from baseline (visit 0) through the final visit (visit 4) with six total clinic visits and daily symptom diaries recording pain and pain medication use. Pain intensity is measured with visual analogue scales for different endometriosis-related pain types and participants complete quality-of-life questionnaires at study visits. The comparison to placebo over several weeks will determine whether Doliral produces meaningful changes in pain scores and quality-of-life measures.
Why it matters
Potential benefit: If successful, Doliral could reduce pelvic pain and improve day-to-day quality of life for some women with endometriosis.
How similar studies have gone: Prior dietary-supplement and nutraceutical trials for endometriosis have shown mixed and mostly preliminary results, with few large, high-quality randomized trials demonstrating clear benefit.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM) classification. * Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and/or ultrasound. * Presence of pelvic pain (VAS \> 4) during the last three months. * No indication for surgical intervention at the time of inclusion in the study. * Patients who are able to provide informed consent. Exclusion Criteria: * Patients under 18 years of age. * Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg/day or naproxen at doses up to 500 mg/day. * Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study. * Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study. * Patients with known allergy or hypersensitivity to Doliral®. * Pregnant or breastfeeding patients. * Patients on sick leave: \> 1 year, or With no intention of returning to work, or Undergoing a disability or permanent incapacity assessment process.
Where it's running
-
Hospital Clínic de Barcelona
Barcelona, Spain Recruiting
Study contacts
- Principal investigator: TAMARA RODRIGUEZ ARAYA, Dr — Hospital Clinic of Barcelona
- Study coordinator: Tamara Rodríguez Araya, Dr
- Email: tlrodriguez@clinic.cat
- Phone: +34 932 27 54 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Endometriosis affecting the urinary tract: long-term outcomes and kidney function
This study looks at how deep endometriosis that touches the urinary tract affects the kidneys over time in adults with hydronephrosis or ureteral blockage.
-
Impact of Endotest on Quality of Life in Endometriosis Patients
This observational cohort study tests how Endotest affects quality of life for women who have a prescription for the test.
-
Ultrasound detection of superficial endometriosis on the uterosacral ligaments
The team will try to see if measuring uterosacral ligament thickness with a transvaginal ultrasound can detect superficial endometriosis in people aged 18–50 scheduled for laparoscopic gynecologic surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.